Amicus Therapeutics Inc. Common Stock (FOLD)

FairStock Score: 21/100 — RISKY

Key Financials

Strengths

• Generates $48 million in annual free cash flow (1.1% yield on market cap)
• Revenue growth of 23.7% demonstrates strong top-line momentum

Concerns

• Altman Z-Score of 0.8 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Amicus Therapeutics Inc. Common Stock is a small-cap healthcare company valued at $4.5 billion. The business generates $634 million in annual revenue with a 0.3% net margin and $48 million in free cash flow. From a quality standpoint, Amicus shows distressed Altman Z-Score of 0.8 warrants caution and negative ROE indicating losses. On valuation, the stock is 0.4% FCF yield. Growth dynamics show revenue growing at 23.7% and profit growth of -88.5%. Our composite FairStock Score of 21/100 reflects below-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Amicus's 24% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $48 million in annual free cash flow (1.1% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer